These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24260284)

  • 21. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
    Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
    Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo.
    Liu Z; Li L; Wu H; Hu J; Ma J; Zhang QY; Ding X
    Drug Metab Dispos; 2015 Feb; 43(2):208-16. PubMed ID: 25409894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.
    Lamba V; Lamba J; Yasuda K; Strom S; Davila J; Hancock ML; Fackenthal JD; Rogan PK; Ring B; Wrighton SA; Schuetz EG
    J Pharmacol Exp Ther; 2003 Dec; 307(3):906-22. PubMed ID: 14551287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
    Mwenifumbo JC; Tyndale RF
    Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
    Nakajima M; Kuroiwa Y; Yokoi T
    Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
    Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
    Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations.
    Kim JH; Cheong HS; Park BL; Kim LH; Shin HJ; Na HS; Chung MW; Shin HD
    Arch Pharm Res; 2015 Jan; 38(1):115-28. PubMed ID: 24988984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.
    Yamazaki H; Inoue K; Hashimoto M; Shimada T
    Arch Toxicol; 1999 Mar; 73(2):65-70. PubMed ID: 10350185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
    Schoedel KA; Sellers EM; Palmour R; Tyndale RF
    Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
    Bloom AJ; von Weymarn LB; Martinez M; Bierut LJ; Goate A; Murphy SE
    Pharmacogenet Genomics; 2013 Dec; 23(12):706-16. PubMed ID: 24192532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents.
    Huang S; Cook DG; Hinks LJ; Chen XH; Ye S; Gilg JA; Jarvis MJ; Whincup PH; Day IN
    Pharmacogenet Genomics; 2005 Dec; 15(12):839-50. PubMed ID: 16272956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
    Miksys S; Lerman C; Shields PG; Mash DC; Tyndale RF
    Neuropharmacology; 2003 Jul; 45(1):122-32. PubMed ID: 12814665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
    Swan GE; Benowitz NL; Lessov CN; Jacob P; Tyndale RF; Wilhelmsen K
    Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.
    Twesigomwe D; Drögemöller BI; Wright GEB; Adebamowo C; Agongo G; Boua PR; Matshaba M; Paximadis M; Ramsay M; Simo G; Simuunza MC; Tiemessen CT; Lombard Z; Hazelhurst S
    Clin Pharmacol Ther; 2024 Mar; 115(3):576-594. PubMed ID: 38049200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
    Nakajima M
    Curr Opin Mol Ther; 2007 Dec; 9(6):538-44. PubMed ID: 18041664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2B6*6 is associated with increased breast cancer risk.
    Justenhoven C; Pentimalli D; Rabstein S; Harth V; Lotz A; Pesch B; Brüning T; Dörk T; Schürmann P; Bogdanova N; Park-Simon TW; Couch FJ; Olson JE; Fasching PA; Beckmann MW; Häberle L; Ekici A; Hall P; Czene K; Liu J; Li J; Baisch C; Hamann U; Ko YD; Brauch H
    Int J Cancer; 2014 Jan; 134(2):426-30. PubMed ID: 23824676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.